On November 3, 2022, X4 Pharmaceuticals, Inc. announced that Dr. Diego Cadavid, its Chief Medical Officer, intends to resign by the end of 2022, and serve as a consultant thereafter. Dr. Cadavid is leaving to pursue an opportunity that closely aligns with his commitment to patients with intractable central nervous system disorders. The Company intends to appoint Dr. Murray Stewart, a member of the Company's Board of Directors, as interim Chief Medical Officer, while the Company conducts a search for a permanent Chief Medical Officer.

Dr. Stewart, who has served as a member of the X4 Board of Directors since March 2019, has had a distinguished career in the life sciences industry, including an 18-year tenure at GlaxoSmithKline (GSK), where he held multiple research and development leadership roles, including Chief Medical Officer, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Dr. Stewart also previously served as Chief Medical Officer of Rhythm Pharmaceuticals, leading the successful NDA submission and approval of ImcivreeTM (setmelanotide), an innovative treatment for rare causes of obesity.